NCT02533427 - Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 29, 2015

Primary Completion Date

March 18, 2016

Study Completion Date

March 18, 2016

Conditions

HCV Infection

Interventions

DRUG

SOF/VEL/VOX

400/100/100 mg FDC tablet administered orally once daily

DRUG

VOX

100 mg tablet administered orally once daily

DRUG

Norgestimate/ethinyl estradiol

Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert

Trial Locations (1)

Christchurch